Sharing a good local news story for patients - early days for the adoption of gene therapies for IRD and to emphasis how new/cutting edge PYC ocular therapies are.
I get the feeling helping patients is what motivates Sue and the PYC team - and are striving hard towards.
The complexity/delivery of current tech is worth noting, PYC will surprise ease of an intravenous injection within a GP type consulting room vs full fledged operating theatre will surprise the industry I think
https://www.insightnews.com.au/sydney-surgeon-details-first-luxturna-gene-therapy-allowing-patient-to-see-stars/#mobile-site-navigation
Interview with Sue Fletcher PYC CSO, page-7
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.005(4.35%) |
Mkt cap ! $559.9M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 12.0¢ | $279.9K | 2.315M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 147929 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 834773 | 5 |
View Market Depth
| Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |